AptarGroup, Inc. (ATR) Stock Price & How to Invest

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. The company runs three reporting segments (Pharma, Beauty, and Closures), with Pharma generating the bulk of profit thanks to long-cycle, regulated, high-margin drug-delivery contracts. Aptar serves a global customer base and positions itself around active material science and delivery precision rather than commodity packaging.

The investment picture is one of a durable, defensive compounder rather than a fast grower. In Q1 2026 reported sales rose about 11% to roughly $983 million, but core (organic) sales were roughly flat, meaning acquisitions and currency drove most of the headline growth while underlying volume stalled. The Pharma segment continues to face a planned multi-year step-down in emergency medicine dispensing sales (about $65 million expected in 2026), while injectables and other pharma lines grow. With a market capitalization near $8.6 billion, a P/E around 23, a beta near 0.4, and 30-plus consecutive years of dividend increases, Aptar reads as a low-volatility, quality-industrial holding.

Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. The planned decline in emergency medicine dispensing sales (about $65 million in 2026) is a known drag on the otherwise strong pharma segment. Beauty and closures are exposed to consumer discretionary weakness, customer destocking, and input-cost swings. Adjusted EBITDA margins have shown compression, and at a P/E near 23 the stock is not cheap for a low-single-digit organic grower. Currency translation adds volatility given the company's large international footprint.

7 analysts publish price targets on ATR, averaging $170.14 against a $130.92 price as of September 2026, or +30.0%. The published targets run from $155.00 to $220.00, a moderate spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ATR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on AptarGroup, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. High-margin pharma drug delivery. The Pharma segment (nasal spray pumps, metered-dose inhaler valves, injectable elastomer components, and active packaging) is the profit engine and carries the highest margins of the three segments. The most optimistic published target, $220.00, assumes this works close to its best case.

The case against. Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. The most pessimistic target, $155.00, is roughly what ATR is worth if this bites instead.

Read the full bull and bear case on ATR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AptarGroup, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.9B
• Q1 2026 sales: ~$983M (+11% reported, ~flat core)
• Q1 2026 adjusted EPS: ~$1.19
• Market cap: ~$8.6B
• P/E ratio: ~23x
• Dividend: ~$1.92/yr (~1.5% yield)

Aptar trades like a quality defensive industrial: a mid-20s earnings multiple, a low beta near 0.4, and a 30-plus year dividend-growth record. The key valuation tension is paying a premium multiple for a business whose organic sales are currently near flat, so the case depends on pharma mix, margin recovery, and eventual beauty and closures reacceleration.

Other names that sit close to ATR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ATR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ATR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ATR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Aptar is a steady, pharma-anchored dispensing specialist whose investment case rests on its healthcare margins and long dividend record rather than rapid growth.

Whether ATR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ATR a buy or a sell?, and where the stock could go from here in the ATR stock forecast.

For income investors, whether ATR pays a dividend and how the payout looks is covered in does ATR pay a dividend? And to weigh ATR against a peer, read the full side-by-side comparisons: ATR vs AG and ATR vs SLGN.